A comparative study of CYP3A4 polymorphisms in Mexican Amerindian and Mestizo populations

Pharmacology

Volumn 81, Issue 2, 2008, Pages 97-103

  Reyes Hernández, Octavio D ^a   Lares Asseff, Ismael ^b   Sosa Macias, Martha ^b   Vega, Libia ^a   Albores, Arnulfo ^a   Elizondo, Guillermo ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Cytochrome P 450 3A4; Drug metabolizing enzymes; Genetic polymorphism

Indexed keywords

CYTOCHROME P450 3A4;

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGED; ALLELE; AMERICAN INDIAN; ARTICLE; ASIAN; CAUCASIAN; COMPARATIVE STUDY; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HISPANIC; HUMAN; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AFRICA; AGED; ASIA; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; HUMANS; INDIANS, CENTRAL AMERICAN; MALE; MEXICO; MIDDLE AGED; NORTH AMERICA; POLYMORPHISM, GENETIC; VARIATION (GENETICS);

EID: 38749126770     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000109983     Document Type: Article

References (31)

1. Watkins PB: Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-184.
2. Kitada M, Kamataki T, Itahashi K, et al: Significance of cytochrome P-450 (P-450 HFLa) of human fetal livers in the steroid and drug oxidations. Biochem Pharmacol 1987;36:453-456.
3. Waxman DJ, Attisano C, Guengerich FP, et al: Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 1988;263:424-436.
4. Shimada T, Yamazaki H, Mimura M, et al: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423.
5. Paine MF, Hart HL, Ludington SS, et al: The human intestinal cytochrome P450 'pie'. Drug Metab Dispos 2006;34:880-886.
6. Thummel KE, Wilkinson GR: In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998;38:389-430.
7. Inaba T, Nebert DW, Burchell B, et al: Pharmacogenetics in clinical pharmacology and toxicology. Can J Physiol Pharmacol 1995;73:331-338.
8. Rodriguez-Antona C, Sayi JG, Gustafsson LL, et al: Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun 2005;338:299-305.
9. Paris PL, Kupelian PA, Hall JM, et al: Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 1999;8:901-905.
10. Kittles RA, Chen W, Panguluri RK, et al: CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification? Hum Genet 2002;110:553-560.
11. Sata F, Sapone A, Elizondo G, et al: CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000;67:48-56.
12. Hsieh KP, Lin YY, Cheng CL, et al: Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 2001;29:268-273.
13. Dai D, Tang J, Rose R, et al: Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 2001;299:825-831.
14. Castaneda-Hernandez G, Hoyo-Vadillo C, Palma-Aguirre JA, et al: Pharmacokinetics of oral nifedipine in different populations. J Clin Pharmacol 1993;33:140-145.
15. Flores-Murrieta FJ, Castaneda-Hernandez G, Granados-Soto V, et al: Increased bioavailability of sildenafil in Mexican men. JAMA 2000;283:1825-1826.
16. Ozdemir V, Kalowa W, Tang BK, et al: Evaluation of the genetic component of variability in CYP3A4 activity: A repeated drug administration method. Pharmacogenetics 2000;10:373-388.
17. Wandel C, Witte JS, Hall JM, et al: CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin Pharmacol Ther 2000;68:82-91.
18. Hesselink DA, van Gelder T, van Schaik RH, et al: Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004;76:545-556.
19. Min DI, Ellingrod VL: Association of the CYP3A4*1B 5′-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2003;25:305-309.
20. Lopes LF, Piccoli Fde S, Paixao VA, et al: Association of CYP3A4 genotype with detection of Vgamma/Jbeta trans-rearrangements in the peripheral blood leukocytes of pediatric cancer patients undergoing chemotherapy for ALL. Leuk Res 2004;28: 1281-1286.
21. Xin X, Luan X, Xiao J, et al: Association study of four activity SNPs of CYP3A4 with the precocious puberty in Chinese girls. Neurosci Lett 2005;381:284-288.
22. Sosa-Macias M, Elizondo G, Flores-Perez C, et al: CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico. J Clin Pharmacol 2006;46:527-536.
23. Reyes-Hernandez OD, Arteaga-Illan G, Elizondo G: Detection of CYP3A4*1B and CYP3A4*2 polymorphisms by RFLP. Distribution frequencies in a Mexican population. Clin Genet 2004;66:166-168.
24. Ball SE, Scatina J, Kao J, et al: Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther 1999;66:288-294.
25. Tayeb MT, Clark C, Ameyaw MM, et al: CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. Pharmacogenetics 2000;10:753-756.
26. Gervasini G, Vizcaino S, Gasiba C, et al: Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and other Caucasian populations. Ther Drug Monit 2005;27:819-821.
27. Cavaco I, Gil JP, Gil-Berglund E, et al: CYP3A4 and MDR1 alleles in a Portuguese population. Clin Chem Lab Med 2003;41:1345-1350.
28. Rais N, Chawla YK, Kohli KK: CYP3A phenotypes and genotypes in North Indians. Eur J Clin Pharmacol 2006;62:417-422.
29. Wang A, Yu BN, Luo CH, et al: Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur J Clin Pharmacol 2005;60:843-848.
30. Hu YF, He J, Chen GL, et al: CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta 2005;353:187-192.
31. Yamamoto T, Nagafuchi N, Ozeki T, et al: CYP3A4*18: it is not rare allele in Japanese population. Drug Metab Pharmacokinet 2003;18:267-268.